Parkinson's Disease Flashcards
Cardinal Motor Symptoms of PD
TRAP: 2 out of 3 (TRA) suggests PD
1. Tremors at Rest
2. Rigidity (Cogwheel)
3. Akinesia (Subjective weakness, facial)
4. Postural Instability
5 Non-motor symptoms associated with PD
- Cognitive (Dementia)
- Psychiatric (Depression, Psychosis)
- Sleep disorder
- Autonomic disorder (Constipation, GI motility, Orthostatic hypotension, Sialorrhea)
- Fatigue
Activities of Daily Living: DEATH
Dressing
Eating
Ambulating
Toileting
Hygiene
Pathophysiology of PD
Dopaminergic Neuron Degeneration in the Substantia Nigra which normally inhibit a number of motor systems
- Hypoactivation of D1 receptors weaken striatal inhibition
- Hypokinesia
Accumulation of toxic Lewy body protein
Nigrostriatal pathway dysfunction
Reduced basal ganglia “action selection” and poor motor control
How to treat drug-induced Parkinsonism?
May not always be reversible
Prevention is key
Anticholinergics and Amantadine can be used
Differentiate drug-induced PD and idiopathic PD
DIP VS iPD
Age Onset: Elderly vs ≥ 60 years old
Symptom Onset: Symmetrical vs Asymmetrical
Time Onset: Acute vs Chronic Progressive
Levodopa Test: Poor vs Marked
List 5 medications associated with drug-induced Parkinsonism
- Antipsychotics
- Anti-seizure Medications
- Antiemetics (Metoclopramide)
- Calcium Channel Blockers (NDHP)
- Lithium, Tetrabenazine, Reserpine, Methyldopa
Drug Classes and MOA for PD management
Central Dopamine Pathway:
1. Levodopa (Synthetic precursor)
2. Dopamine agonists (Pramipexole, Rotigotine)
3. MAO-B Inhibitors (Selegiline, Rasagiline)
4. COMT Inhibitors (Entacapone)
Other Pathways to correct Imbalance:
1. Anticholinergics (Trihexyphenidyl)
2. NMDA Receptor Antagonist (Amantadine)
Levodopa Brands, Combinations, Formulations and Rationale
Combination with Carbidopa / Benserazide
- DCI 75-100 mg required
- Peripheral Conversion by DOPA decarboxylase in the gut => DCI increases bioavailability
Brands (L-dopa : DCI)
- Sinemet (1:4, 1:10)
- Madopar (1:4)
Formulation
- Immediate or Controlled / Modified Release
- Considerations for wearing off effect
Levodopa ADME, DDI and considerations for counseling
Absorption is affected by protein and fat intake because levodopa is absorbed by an active saturable carrier system for large neutral amino acids. Take on empty stomach.
Drug Interactions:
- Pyridoxine high dose (Not a problem if DCI combination as pyridoxine is a cofactor for DOPA decarboxylase)
- Iron: Space out administration
- Protein: Space out administration
- Dopamine antagonists (Antipsychotics, antiemetics): Antiemetic of choice is domperidone
Levodopa ADRs and when does dyskinesia commonly onset?
- GI effects: N/V
- DA effects: Orthostatic Hypotension
- CNS effect: Drowsy, sudden sleep onset, hallucination, psychosis
- Long term: Dyskinesia (After 3 to 5 years of initiation)
What is dyskinesia? How do you manage it?
Involuntary uncontrollable twitching, jerking, and dystonia
Add amantadine or replace specific doses with CR Levodopa
List 2 motor complications of levodopa and how to manage them
- On-off Phenomena: Unpredictable
- Wearing Off Effect as disease progresses:
- Modify timing of medication intake
- Modify formulation use
(Increased to 4-6h release period)
Formulation conversion for levodopa
IR to CR: Increase the dose by 25-50%
Types of dopamine agonists and the disadvantage of one over the other
Ergot: Lower bioavailability (First pass)
- Bromocriptine
- Cabergoline
- Pergolide
Non-ergot
- Rotigotine (Transdermal)
- Pramipexole
- Apomorphine (Subcut)
- Ropinirole